Endocyte, Inc.

$ECYT - Nasdaq - Pharmaceuticals and Biotechnology
0 LAST
0 CHANGE $
0 CHANGE %
loader
ON 1
WATCHLISTS

COMMUNIQUÉ DETAILS

posts/post

Press Release $ECYT Endocyte, Inc.

Up 0 0 Down
Endocyte Announces Presentations at the 246th American Chemical Society Meeting & Exposition

WEST LAFAYETTE, Ind., Sept. 9, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that three posters featuring Endocyte's platform technology for the generation of SMDCs for multiple diseases will be presented by Endocyte scientists at the 246th American Chemical Society (ACS) Meeting & Exposition to be held in Indianapolis, Sept. 8 – 12, 2013.

"Over the past years, impressive clinical data have demonstrated the significance and potential of Endocyte's highly versatile technology platform for developing SMDCs toward folate-receptor (FR)-specific targeting," said Iontcho Vlahov, Ph.D., vice president of discovery chemistry. "Endocyte continues to develop its broad pipeline, and our data demonstrate the potential of Endocyte's platform technology for other molecular targets and diseases. Amongst others, we will present structure-activity relationship studies for another guidance system, leading to 'tailored' prostate-specific-membrane-antigen (PSMA)-targeted conjugates of tubulysin, a super-potent chemotherapeutic agent."

Presentations are as follows:

Abstract #:   294
Title:    "Total synthesis of tubulysins and their folate-receptor targeting conjugates: A new chemical reaction leads to analogs with enhanced cytotoxicity" 
When:    Wednesday, Sept. 11, 2013, 7 p.m. – 10 p.m. EDT
Session ID:    General Poster Session 
Location:   Indiana Convention Center, Room: Sagamore 5-7 
     
Abstract #:    298
Title:    "Prostate-specific membrane antigen targeted tubulysin conjugates for cancer therapy" 
When:    Wednesday, Sept. 11, 2013, 7 p.m. – 10 p.m. EDT
Session ID:    General Poster Session 
Location:    Indiana Convention Center, Room: Sagamore 5-7 
     
Abstract #:    330
Title:    "Synthesis of novel prodrugs of highly potent doxorubicin analogs and their conjugates" 
When:    Wednesday, Sept. 11, 2013, 7 p.m. – 10 p.m. EDT
Session ID:    General Poster Session 
Location   Indiana Convention Center, Room: Sagamore 5-7 

About Endocyte

Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease expresses the molecular target of the therapy and who are therefore more likely to benefit from treatment. Targeted SMDCs for cancer, inflammatory disorders and kidney disease are in preclinical development. For additional information, please visit Endocyte's website at www.endocyte.com.

CONTACT: Stephanie Ascher, Stern Investor Relations, Inc.,
         (212) 362-1200, stephanie@sternir.com

         Martina Schwarzkopf, Ph.D., Russo Partners,
         (212) 845-4292, martina.schwarzkopf@russopartnersllc.com

         Tony Russo, Ph.D., Russo Partners,
         (212) 845-4251, tony.russo@russopartnersllc.com
Source: Endocyte, Inc.
SHARE THIS: Twitter StockTwits LinkedIn Google Plus SHORT URL: http://bdvt.co/bOQW

SIGN IN TO BOARDVOTE

FORGOT PASSWORD?